Team:Virginia/ProjectDesign

• PROJECT
  • DESIGN
  • MODELING
  • EXPERIMENTS
  • PARTS
  • SUMMARY
• HUMAN PRACTICES
  • INTERVIEWS
  • SURVEY
  • SAFETY GUIDELINES
  • POLICY PROPOSAL
  • PUBLIC EDUCATION
  • iGEM OUTREACH
  • BUSINESS
• TEAM
  • TEAM MEMBERS
  • COLLABORATIONS
  • ATTRIBUTIONS
• DOCUMENTATION
  • NOTEBOOK
  • SAFETY
  • REFERENCES

← Project Overview Modeling →

The Process

To create an effective biocontainment system, when implemented into a target cell, our system must restrict the cell in such a way that it only grows and replicates when a non-natural metabolite is present. Cells using this system will be unable to survive outside of controlled environments, reducing the risk of escape. To accomplish this goal, we aimed to select a protecting group for leucine and a corresponding cleavage enzyme to remove the protecting group, and to replace the wild-type leucyl-tRNA synthetase with a mutant leucyl-tRNA synthetase of our design.

The biocontainment functionality of this system begins at metabolite uptake. The cell must be able to take up a non-natural metabolite that is not typically readily available in the environment. We needed to select an essential metabolite to the cell so that without that metabolite, the cell would die. Amino acids are key precursors to all proteins. We chose to modify the amino acid leucine. The non-natural modified leucine, after uptake, would then be charged with tRNA molecule to become a modified-leucine-tRNA molecule via a synthetase enzyme. However, this step requires a modified synthetase so that the modified leucine, rather than wild-type leucine, is preferentially charged with tRNA.

Next, the charged protected-leucyl-tRNA molecule must have its protecting group removed. Once its protecting group is removed, the wild-type leucyl-tRNA can continue on to polypeptide formation. In this way, the cell is incorporating normal leucine amino acids into proteins, while still being reliant on protected leucine.

Protecting Group

Our protecting group needs to bind to the N-terminus of leucine, as the C-terminus of the amino acid has to bind to tRNA. Through research and experimentation, we determined that N-carbobenzyloxy-leucine (CBZ-leucine) was the best protecting group for our purposes.

Cleavage Enzyme

The cleavage enzyme will remove the CBZ group from the CBZ-leucyl-tRNA, allowing for normal leucine to be incorporated normally into polypeptides.

Mutant Leucyl-tRNA Synthetase

This synthetase, designed using our protein modeling software MUT, is designed to preferentially bind CBZ-leucine with tRNA, and hydrolyze any wild-type leucine-tRNA that forms.

Implementation of the system

To implement this system completely, the genes for both the CBZ cleavage enzyme and for the mutant leucyl-tRNA synthetase need to be readily transcribed and translated into functional proteins in the organism. Additionally, to ensure that leucine is not usable in the organism's metabolism, the wild-type leucyl-tRNA synthetase gene needs to be knocked out. In this way, we would guarantee that the organism cannot survive without supplementation of the CBZ leucine.